Preventive role of genistein in an experimental non-alcoholic steatohepatitis model

• Published in: Journal of gastroenterology and hepatology 2007-11, Vol.22 (11), p.2009-2014
• Main Authors: Yalniz, Mehmet, Bahcecioglu, Ibrahim Halil, Kuzu, Nalan, Poyrazoglu, Orhan Kursat, Bulmus, Ozgur, Celebi, Selman, Ustundag, Bilal, Ozercan, Ibrahim Hanefi, Sahin, Kazim
• Format: Article
• Language: English
• Subjects: Alanine Transaminase - blood; Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Antioxidants - pharmacology; Antioxidants - therapeutic use; Aspartate Aminotransferases - blood; Biological and medical sciences; Dietary Fats; Disease Models, Animal; Fatty Liver - blood; Fatty Liver - metabolism; Fatty Liver - pathology; Fatty Liver - prevention & control; Gastroenterology. Liver. Pancreas. Abdomen; genistein; Genistein - pharmacology; Genistein - therapeutic use; Hepatitis - blood; Hepatitis - metabolism; Hepatitis - pathology; Hepatitis - prevention & control; high fat diet; isoflavones; Lipid Peroxidation - drug effects; Liver - drug effects; Liver - enzymology; Liver - metabolism; Liver - pathology; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Malondialdehyde - blood; Malondialdehyde - metabolism; Medical sciences; non-alcoholic steatohepatitis; Organ Size; Other diseases. Semiology; oxidative stress; Oxidative Stress - drug effects; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta - blood; Tumor Necrosis Factor-alpha - blood
• ISSN: 0815-9319; 1440-1746
• DOI: 10.1111/j.1440-1746.2006.04681.x

Background and Aim:  The aim of the present study was to evaluate the preventive role of genistein, a phytoestrogen with a wide variety of pharmacological effects, in an experimental non‐alcoholic steatohepatitis (NASH) model. Methods:  Thirty‐six Sprague‐Dawley rats were divided into three groups. Group 1 (control) received only a standard rat diet, group 2 (placebo) was given a high fat diet (HFD) plus 0.5 mL/day saline subcutaneously, and group 3 (genistein group) a HFD plus subcutaneous genistein injection at dose of 0.2 mg/kg/day for 6 weeks. All rats were killed after 6 weeks. Serum aminotransferases, tumor necrosis factor (TNF)‐α, transforming growth factor (TGF)‐β, and plasma and liver malondialdehyde (MDA) levels were measured. Additionally, steatosis, ballooning degeneration and inflammation of the liver were examined histopathologically. Results:  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (P